ArticleExperimental and therapeutic medicine2015
microRNA-375 inhibits osteogenic differentiation by targeting runt-related transcription factor 2.
Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 44 citations in OpenAlex.
- Research progress on the regulation of miRNAs in diabetic kidney disease and osteoporosis.International journal of clinical and experimental pathology · 2026Review
- Circulating miRNAs are associated with successful bone regeneration.Frontiers in bioengineering and biotechnology · 2025Article
- MiR-331-3p facilitates osteoporosis and may promote osteoporotic fractures by modulating NRP2 expression.Journal of orthopaedic surgery and research · 2024Article
- CircCOX6A1 suppresses osteogenic differentiation and aggravates osteoporosis via miR-512-3p/DYRK2 axis.Molecular biology reports · 2024Article
- Oxidative Stress and Inflammation in Osteoporosis: Molecular Mechanisms Involved and the Relationship with microRNAs.International journal of molecular sciences · 2023Review
- Regulatory mechanisms of microRNAs in endocrine disorders and their therapeutic potential.Frontiers in genetics · 2023Review
- MicroRNAs within the Basal-like signature of Quadruple Negative Breast Cancer impact overall survival in African Americans.Scientific reports · 2022Article
- Osteoporosis pathogenesis and treatment: existing and emerging avenues.Cellular & molecular biology letters · 2022Review
- Effect of Anti-Osteoporotic Treatments on Circulating and Bone MicroRNA Patterns in Osteopenic ZDF Rats.International journal of molecular sciences · 2022Article
- LncRNA BC083743 Silencing Exacerbated Osteoporosis by Regulating the miR-103-3p/SATB2 Axis to Inhibit Osteogenic Differentiation.Computational intelligence and neuroscience · 2022Article
- Circulating miR-122-5p and miR-375 as Potential Biomarkers for Bone Mass Recovery after Parathyroidectomy in Patients with Primary Hyperparathyroidism: A Proof-of-Concept Study.Diagnostics (Basel, Switzerland) · 2021Article
- Diagnostic Performance of a Panel of miRNAs (OsteomiR) for Osteoporosis in a Cohort of Postmenopausal Women.Calcified tissue international · 2021Article
- miRNAs Related to Different Processes of Fracture Healing: An Integrative Overview.Frontiers in surgery · 2021Review
- The role of microRNAs in the osteogenic and chondrogenic differentiation of mesenchymal stem cells and bone pathologies.Theranostics · 2021Review
- Effects of lncRNA TUSC7 on the malignant biological behavior of osteosarcoma cells via regulation of miR-375.Oncology letters · 2020Article
- The roles of miRNA, lncRNA and circRNA in the development of osteoporosis.Biological research · 2020Review
- The potential function of miR-135b-mediated JAK2/STAT3 signaling pathway during osteoblast differentiation.The Kaohsiung journal of medical sciences · 2020Article
- miRNA-429 suppresses osteogenic differentiation of human adipose-derived mesenchymal stem cells under oxidative stress via targeting SCD-1.Experimental and therapeutic medicine · 2020Article
- The Roles of Epigenetics Regulation in Bone Metabolism and Osteoporosis.Frontiers in cell and developmental biology · 2020Review
- Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.Current opinion in nephrology and hypertension · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
microRNAs (miRNAs) are involved in the regulation of almost all physiological and pathological processes, including osteoblast proliferation and differentiation. miR-375 has been reported to be aberrantly expressed in various tumor types and to inhibit cell proliferation and invasion by targeting a number of key genes. However, the effects of miR-375 on osteogenic differentiation have not been investigated. Thus, the present study aimed to elucidate the function served by miR-375 in osteogenic differentiation. The expression levels of miR-375 were observed to decrease in a C2C12 cell model of osteogenic differentiation. Overexpression of miR-375 inhibited the activity of key osteoblast markers, including osteocalcin (OC), alkaline phosphatase (ALP) and collagen, type I, α 1 (COL1A1). By contrast, inhibition of miR-375 expression resulted in an increase in the osteogenic potential, as indicated by the enhanced expression levels of OC, ALP and COL1A1. In addition, a dual-luciferase reporter assay indicated that runt-related transcription factor 2 (RUNX2) was a target of miR-375. Western blot analysis revealed that the inhibition of miR-375 led to a significant increase in the protein expression levels of RUNX2. In addition, overexpression of RUNX2 was observed to attenuate the miR-375-mediated suppression of osteogenic differentiation. Therefore, the results demonstrated that miR-375 was able to inhibit osteogenic differentiation via the regulation of RUNX2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.